Get the Stockscreener App
0.9922
2.73%
-0.0278
After Hours:
1.00
0.0078
+0.79%
Ocugen Inc stock is traded at $0.9922, with a volume of 4.02M.
It is down -2.73% in the last 24 hours and down -23.68% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.02
Open:
$1.01
24h Volume:
4.02M
Relative Volume:
0.79
Market Cap:
$282.85M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.6816
EPS:
-0.37
Net Cash Flow:
$-72.53M
1W Performance:
-4.60%
1M Performance:
-23.68%
6M Performance:
-39.50%
1Y Performance:
+148.05%
1-Day Range:
$0.96
$1.03
1-Week Range:
$0.9359
$1.06
52-Week Range:
$0.345
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Profund Advisors LLC Invests $227,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MSN
Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares - openPR
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Victory Capital Management Inc. Makes New $51,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
OFS Credit Company, Inc. Prices Preferred Stock Offering - StockTitan
OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
How to Take Advantage of moves in (OCCIN) - Stock Traders Daily
OFS Credit to offer preferred stock in public offering - MSN
Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference - GlobeNewswire
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference - StockTitan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Is OCGN’s price to cash per share ratio a concern for investors? - US Post News
Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha
Olivia Faith Robinson Georgia Obituary - Rebellion Research
Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World
Bank of New York Mellon Corp Buys 725,536 Shares of Ocugen, Inc. (NASDAQ:OCGN) - MarketBeat
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Taking the lead: Organon & Co. (OGN) - SETE News
All the Doctor Odyssey guest stars we know so far - Hidden Remote
Ocugen Inc. stock remains steady Wednesday, still outperforms market - MarketWatch
Daiwa Securities Group Inc. Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 - Seeking Alpha
NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation - AccessWire
NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation - Newswire
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Investigation announced for Long-Term Investors in shares of Ocugen, Inc. (NASDAQ: OCGN) - openPR
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment - Nasdaq
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and - EIN News
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - Ocugen
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to - GlobeNewswire
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - StockTitan
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference - MSN
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit - GlobeNewswire
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit - StockTitan
Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference - MyChesCo
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Ocugen
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Ocugen Advances Gene Therapy Trial for Stargardt Disease - MSN
Short Interest in Ocugen, Inc. (NASDAQ:OCGN) Decreases By 19.9% - MarketBeat
TSX Information Tech Capped Index (TTTK) QuotePress Release - The Globe and Mail
TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail
Ocugen Advances Gene Therapy Trial for Stargardt Disease - MyChesCo
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):